Om avsnittet
Friday, October 23, 2026
In today's episode, Dr. Alok Patel (@alokpatelmd) & Adam Rose (@adjoro) cover a phase three trial of nicotinamide riboside in early Parkinson disease. Over 52 weeks, the supplement boosted NAD metabolism but showed no clinical benefit, raising questions for NAD boosting strategies. They also walk through a large hospital comparison of phenobarbital and diazepam for alcohol withdrawal, with similar stays and ventilation rates and fewer self directed discharges on phenobarbital, and why diazepam protocols may stay the course pending randomized trials. Plus: they also discuss national measles trends, FDA warning letters to Amazon and Walmart, and more.
Coverage Timeline:
(00:00) Intro (01:05) NR Supplement Trial for Parkinson's (03:01) NAD Supplements & Influencer Hype (04:49) Phenobarbital vs. Diazepam (07:30) Measles Surge in US (08:27) New Sunscreen Ingredient BEMT (09:01) Blood Clots
Have a story, think we missed something, want to say hi, or curious to learn about the Medlines team? Visit www.medlinespod.com or email [email protected].
Sources & Media Attributions for Today's Episode Available At: www.medlinespod.com/sources
Medlines is a Human Content Production
Fler avsnitt
Visa alla avsnitt av MedlinesMedlines med Human Content, Inc. finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.